A Stratified Approach for Managing Patients With Low Back Pain in Primary Care (SPLIT Program): A Before-and-After Study

Luís Antunes Gomes, MSc^{1,2,3}
Rita Fernandes, PhD^{1,3}
Carmen Caeiro, PhD³
Ana Rita Henriques, MSc^{1,2}
Rute Dinis de Sousa, MSc, MBA^{1,2}
Jaime C. Branco, MD, PhD^{1,2,4}
Fernando Pimentel-Santos, MD, PhD^{1,4}
Rubina Moniz, MSc^{3,5}
Lilia Vicente⁵
Helena Canhão, MD, PhD, ^{1,2,6}
Ana Maria Rodrigues, MD, PhD^{1,2,7}
Eduardo Brazete Cruz, PhD^{1,3}

¹Comprehensive Health Research Centre (CHRC), NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal

²EpiDoC Unit, NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal

³Departamento de Fisioterapia, Escola Superior de Saúde, Instituto Politécnico de Setúbal, Setubal, Portugal

⁴Serviço de Reumatologia do Hospital Egas Moniz - Centro Hospitalar Lisboa Ocidental (CHLO-EPE), Lisbon, Portugal

⁵Agrupamento de Centros de Saúde da Arrábida - Administração Regional de Saúde de Lisboa e Vale do Tejo (ACeS Arrábida – ARSLVT), Setúbal, Portugal

⁶Unidade de Reumatologia, Centro Hospitalar Universitário Lisboa Central - Hospital Santo António dos Capuchos (CHULC-EPE), Lisbon, Portugal

⁷Unidade de Reumatologia, Hospital dos Lusíadas, Lisbon, Portugal



Conflicts of interest: authors report none.

CORRESPONDING AUTHOR

Luís Antunes Gomes Comprehensive Health Research Centre NOVA Medical School Universidade NOVA de Lisboa Rua Câmara Pestana 6 1150-082, Lisbon, Portugal ftluisgomes@gmail.com

ABSTRACT

PURPOSE To determine the effects of stratified primary care for low back pain (SPLIT program) in decreasing back-related disability for patients with low back pain (LBP) in primary care.

METHODS We conducted a before-and-after study. We compared health-related outcomes for 2 sequential, independent cohorts of patients with LBP recruited at 7 primary care units in Portugal. The first prospective cohort study characterized usual care (UC) and collected data from February to September 2018. The second was performed when the SPLIT program was implemented and collected data from November 2018 to October 2021. Between cohorts, physical therapists were trained in the implementation of the SPLIT program, which used the STarT Back Screening Tool to categorize patients for matched treatment. We compared back-related disability (Roland-Morris Disability Questionnaire, 0-24 points), pain (Numeric Pain Rating Scale, 0-10 points), perceived effect of treatment (Global Perceived Effect Scale, -5 to +5 points), and health-related quality of life (EuroQoL 5 dimensions 3 levels index, 0-1 points).

RESULTS We enrolled a total of 447 patients: 115 in the UC cohort (mostly treated with pharmacologic treatment) and 332 in the SPLIT cohort (all referred for a physical therapy intervention program). Over the study period of 6 months, patients in the SPLIT program showed significantly greater improvements in back-related disability (β , -2.94; 95% CI, -3.63 to -2.24; $P \le .001$), pain (β , -0.88; 95% CI, -1.18 to -0.57; $P \le .001$), perceived effect of treatment (β , 1.40; 95% CI, 0.97 to 1.82; $P \le .001$), and health-related quality of life (β , 0.11; 95% CI, 0.08 to 0.14; $P \le .001$) compared with UC.

CONCLUSIONS Patients in the SPLIT program for LBP showed greater benefits regarding health-related outcomes than those receiving UC.

Ann Fam Med 2024;22:195-202. https://doi.org/10.1370/afm.3104

INTRODUCTION

ow back pain (LBP) is a high-burden health problem worldwide, and its management represents a serious challenge for health systems.¹⁻⁴ The burden caused by LBP is mainly explained by the great disability it causes in a minority of patients, those with persistent, disabling pain.^{5,6}

To decrease the number of patients who develop persistent, disabling LBP, the implementation of a stratified approach in primary care has been suggested. The Using the STarT Back Screening Tool (SBST) to categorize patients according to low, medium, and high risk of developing poor disability, this approach suggests matched physical therapy treatments of increasing complexity according to risk subgroup.

The STarT Back trial was the first study to show the effectiveness and cost-effectiveness of the stratified approach for LBP.^{12,13} Aiming to generalize these results, the IMplementation to improve Patient Care through Targeted treatment (IMPaCT) study confirmed the potential of this approach for improving patient-level outcomes while decreasing the consumption of health care in the routine clinical practice of a UK primary care setting.^{14,15}

Considering that health systems are context specific and might vary substantially between countries, several studies sought to adapt and test the stratified approach in primary care. ¹⁶⁻²⁰ A country that might benefit from such a


comprehensive approach is Portugal. In addition to being the major cause of disability-adjusted life-years, LBP management in Portuguese primary care is described as fragmented and not aligned with clinical recommendations. Given this scenario, we aimed to determine the effects of stratified primary care for low back pain (SPLIT) in decreasing back-related disability for patients seeking primary care for an LBP episode.

METHODS

Design and Setting

The SPLIT study used a before-and-after design embedded in Portuguese primary care.²³ This is an integral part of the public National Health System and is geographically organized within regional health administrations that manage a set of health center groups, which in turn includes a set of health units to which residents are assigned. The present study was developed under a protocol with the Regional Health Administration of Lisbon and Tagus Valley (ARS-LVT) via its Arrábida health center group. With a total of 23 health units, this health center group is responsible for 242,928 patients from 3 geographic regions (Palmela, Sesimbra, Setubal).

Two sequential, independent cohorts of patients with LBP were recruited at 7 health units according to the different study phases. These units were chosen considering the proportion of geographic area covered (Palmela, Sesimbra, Setubal) and the presence of primary care—based physical therapists (PTs) in these workplaces. In Phase 1, a cohort of patients (usual care [UC] cohort) was recruited to characterize UC and patients' health-related outcomes (February-September 2018). Slightly before the end of this phase, a training and mentoring program (Phase 2) aiming to optimize the implementation of the SPLIT program in the routine clinical practice of the 4 participating PTs was developed and executed (September 2018-August 2019). In Phase 3, a new cohort of patients (SPLIT cohort) was recruited to evaluate the outcomes of the SPLIT program (November 2018-October 2021). The longer recruitment period of Phase 3 represents a deviation from the protocol and is mainly explained by the constraints associated with the coronavirus disease 2019 (COVID-19) pandemic. The decision to increase the



recruitment period aimed to prevent access restrictions to health care during the pandemic from affecting the future maintenance of the SPLIT program. The study was approved by the Ethics Committee of ARS-LVT (REF 3562/CES/2018); its framework is presented in Figure 1.

Participants

Participants were eligible if they had consulted a participating family physician (FP) for nonspecific LBP^{24,25} of any duration, with or without leg pain; were aged 18-65 years; and were able to read and speak the Portuguese language. Exclusion criteria were clinical signs of infection, tumor, osteoporosis, fracture, inflammatory disorder, radicular syndrome, severe depression or other psychiatric condition, pregnancy, or having undergone back surgery or conservative treatment within the previous 6 or 3 months, respectively.

Phase 1: Usual Care Cohort

Patients from participating health units were recruited consecutively by their attending FP. Patients were invited to participate and asked to be contacted by a trained research assistant (RA), who confirmed eligibility criteria and informed them about the study. For those who consented, sociodemographic and clinical data (including back-related disability, pain, and health-related quality of life [HRQoL]) were collected by the RA by interview, using a standard data collection form.

In this phase, FPs were not aware of the SPLIT program; they were encouraged to manage patients as usual based on their clinical judgment. Monthly debriefing meetings were scheduled to motivate participating FPs regarding the recruitment process. The course of outcomes for this cohort is published elsewhere.²¹

Phase 2: Training and Mentoring Program

The SPLIT program consisted of a structured physical therapy program informed by the theoretical rationale and interventions suggested by the STarT Back Trial²⁶ and other frameworks. After each patient's initial FP consultation and referral, the following 3 main steps were taken: (1) clinical assessment by a trained PT, including use of the SBST, for stratification of risk of poor disability, (2) matched treatment,

and (3) a monitoring program to track outcomes (Supplemental Appendix).

Considering the lack of involvement of primary care—based PTs within the clinical pathway for LBP and the potential challenges implementation of the SPLIT program would entail, ³¹ we developed a training program for PTs, which comprised a 30-hour course delivered by 4 PTs with expertise in training clinicians. To consolidate the knowledge and confidence of participating PTs, ³¹ we executed a mentoring program involving monthly contacts over a period of 12 months to provide peer feedback and clinical

case review. To present the SPLIT program and motivate FPs regarding the recruitment and referral procedures, we organized 2 interactive group-based sessions, in which the best evidence on the effects of nonpharmacologic interventions for LBP was presented.^{7,8,32-34} Two rheumatologists and 2 PTs moderated these sessions. Monthly debriefing meetings continued to be scheduled.


Phase 3. SPLIT Cohort

Participating FPs from the same 7 health units were asked to keep the recruitment process used for Phase 1. They were again encouraged to manage patients as usual, except for the referral of potentially eligible participants who should be referred to primary care—based PTs for evaluation and treatment. After referral, participating PTs confirmed the eligibility criteria and informed patients about the study, inviting them to participate. For those who consented,

sociodemographic and clinical data were collected using the same procedures as for Phase 1. The decision to entrust participating PTs with the responsibility of collecting patients' data aimed to optimize the implementation of the SPLIT program. Because it included, for clinical reasoning purposes, the collection of clinical data that were used later as study outcomes (ie, back-related disability and pain intensity), this decision prevented the duplication of data collection and thus decreased patients' burden with regard to answering questionnaires.

Health-Related Outcomes

Health-related outcomes were assessed at 2- and 6-month follow-ups (by telephone) by the RA (UC cohort) and participating PTs (SPLIT cohort). The use of telephone interviews was established to potentiate patient retention. Training was provided to standardize data collection procedures. The



primary outcome was back-related disability measured with the Portuguese version of the Roland-Morris Disability Questionnaire (RMDQ) (0-24 points [greater scores indicating greater disability]). $^{35-37}$ Secondary outcomes included pain intensity, HRQoL, and perceived effect of treatment. For pain intensity, the Portuguese version of the Numeric Pain Rating Scale (NPRS) was used (0 = no pain, 10 = worst possible

pain). $^{38-40}$ The HRQoL was measured with the EuroQol 5-dimension 3-level (EQ-5D-3L), a generic instrument suggesting an index of the individual health status (1 = the best possible health, 0 = death). 41,42 The weight applied was based on the Portuguese valuation study. 43 The Global Perceived Effect Scale (GPES) measured the perceived effect of treatment (-5 = vastly worse, +5 = completely recovered). $^{44-46}$

Table	1.	Baseline	Characteristics	of	Participants
-------	----	----------	-----------------	----	--------------

lable 1. Baseline Characteristics of Participants					
	Total (n = 447)	UC (n = 115)	SPLIT (n = 332)	P Value	
Sociodemographic					
Age, y, mean (SD)	46.19 (11.65)	48.06 (11.41)	45.46 (11.75)	.035ª	
Female, No. (%)	268 (60.0)	65 (56.5)	203 (61.1)	.383 ^b	
BMI (kg/m²), No. (%)				.872 ^b	
Underweight or normal weight,	174 (39.4)	46 (40.0)	128 (39.1)		
Overweight or obesity	268 (60.6)	69 (60.0)	199 (60.9)		
Marital status, No. (%)				.937b	
Lives alone	158 (35.3)	41 (35.7)	117 (35.2)		
Lives with someone	289 (64.7)	74 (64.3)	215 (64.8)		
Years of education, No. (%)				.365b	
0-9	216 (48.5)	60 (52.2)	156 (47.3)		
≥10	229 (51.5)	55 (47.8)	174 (52.7)		
Work status, No. (%)				.068b	
Active	314 (70.7)	89 (77.4)	225 (68.4)		
Not working	130 (29.3)	26 (22.6)	104 (31.6)		
Clinical					
Duration of LBP episode, No. (%)				.618 ^b	
< 12 weeks	231 (51.9)	62 (53.9)	169 (51.2)		
≥12 weeks	214 (48.1)	53 (46.1)	161 (48.8)		
Referred leg pain, No. (%)	206 (46.5)	76 (66.1)	130 (39.6)	≤.001 ^b	
LBP pain medication, No. (%)	225 (51.1)	66 (57.4)	159 (48.9)	.118 ^b	
Sickness certificate, No. (%)	95 (21.6)	31 (27.0)	64 (19.7)	.104 ^b	
SBST risk subgroup, No. (%)				≤.001 ^b	
Low	174 (38.9)	20 (17.4)	154 (46.4)		
Medium	189 (42.3)	62 (53.9)	127 (38.3)		
High	84 (18.8)	33 (28.7)	51 (15.4)		
SBST psychosocial subscale (Q5-9, 0-5), mean (SD)	2.20 (1.45)	2.78 (1.28)	2.00 (1.45)	≤.001ª	
Back-related disability (RMDQ, 0-24), mean (SD)	9.46 (6.18)	12.63 (5.90)	8.37 (5.89)	≤.001ª	
Pain intensity (NPRS, 0-10), mean (SD)	4.23 (2.61)	5.41 (2.56)	3.83 (2.50)	≤.001ª	
HRQoL (EQ-5D-3L, 0-1), mean (SD)	0.56 (0.25)	0.44 (0.23)	0.61 (0.25)	≤.001ª	

BMI = body mass index; EQ-5D-3L = EuroQoL 5 dimensions 3 levels; HRQoL = health-related quality of life; LBP = low back pain; NPRS = Numeric Pain Rating Scale; Q5-9 = Questions 5-9; RMDQ = Roland-Morris Disability Questionnaire; SBST = STarT Back Screening Tool; SPLIT = stratified primary care for low back pain; UC = usual care.

Note: Sample size was not consistent, owing to missing data. Total: BMI (n = 442); years of education (n = 445); work status (n = 444); duration of LBP episode (n = 445); referred leg pain (n = 443); pain medication (n = 440); sickness certificate (n = 440). SPLIT: BMI (n = 327); years of education (n = 330); work status (n = 329); duration of LBP episode (n = 330); referred leg pain (n = 325); pain medication (n = 325); sickness certificate (n = 325).

Statistical Analysis

We used descriptive statistics to characterize both cohorts of participants. Baseline differences between cohorts were tested with the Mann-Whitney test (continuous variables) and the χ^2 test (categorical variables).

We used linear mixed-effects models to compare cohorts regarding the RMDQ, NPRS, GPES, and EQ-5D-3L index over follow-up (ie, baseline, 2- and 6-month time points). Because we also considered the proportion of patients who met the minimum important change (MIC) criteria (ie, ≥30% decrease from baseline for RMDQ and NPRS and a GPES score \geq 3)^{46,47} and those with poor disability (RMDQ ≥7),11 we also used logistic mixed-effects models. All of the models included varying intercepts for each participant and an identity covariance structure. For outcomes that were not measured at baseline (ie, GPES and MIC outcomes), the 2-month follow-up was considered the models' first time point.

Given the observational nature of the study and the consequent probability of confounding, we adjusted models for baseline imbalances between cohorts (ie, age; referred leg pain; and baseline SBST psychosocial subscale, NPRS, RMDQ, and EQ-5D-3L values) and clinically important characteristics (ie, duration of LBP episode). Despite some of these measures having been collected at all 3 time points, they were entered into the models as time independent to address baseline discrepancies.

We conducted a sensitivity analysis to investigate whether the deviation from the protocol regarding recruitment time influenced the results. This followed the procedures

^a Mann-Whitney test.

 $^{^{\}rm b}$ $\chi^{\rm 2}$ test.

described for the main analysis; however, for the SPLIT cohort, only those participants recruited from September 2018 to August 2019 were considered. For exploratory purposes, we also conducted a descriptive analysis of outcomes considering the SBST risk subgroups (low, medium, and high risk). STarT Back Screening Tool scoring methods are presented in the Supplemental Appendix. Given the low proportion of missing data, statistical methods for handling missing date were not considered. A significance level of 5% was used. All analyses were performed with SPSS Statistics version 23 (IBM).

RESULTS

A total of 447 participants were included in the study: 115 in the UC cohort and 332 in the SPLIT cohort (Figure 2). For

the SPLIT cohort, most of the included participants (173 [52.1%]) were referred during the first 12 months. The remaining 78 (23.5%) and 81 (24.4%) were referred during the second and third years of recruitment, respectively.

In Phase 1 (UC cohort), patients were predominantly treated by FPs with pharmacologic treatment (85.3%). Nonsteroidal anti-inflammatory drugs (81.4%) and muscle relaxants (60.8%) were the most common, followed by weak opioids (19.6%). Only 8.3% of patients were referred for physical therapy, namely to community clinics not related to primary care. In Phase 3, all patients in the SPLIT cohort were referred to trained primary care—based PTs. A mean (SD) of 3.76 (3.70) physical therapy sessions were provided: 1.11 (0.71) for patients with low risk, 4.48 (2.52) for medium risk, and 9.98 (3.31) for high risk.

Participant Characteristics

Participants had a mean (SD) age of 46.19 (11.65) years and were predominantly female (268 [60.0%]) and employed (314 [70.7%]) (Table 1). Except for the older age of the SPLIT cohort (P = .035), sociodemographic characteristics were similar between cohorts. Clinically, LBP-related symptoms were generally less severe in participants in the SPLIT cohort ($P \le .001$); they had less referred leg pain, risk of poor disability, back-related disability, pain, and increased HRQoL compared with the UC cohort.

Health-Related Outcomes

With respect to the 6-month follow-up period, there was a significant and superior improvement in back-related disability for the SPLIT cohort compared with the UC cohort (ß,

-2.94; 95% CI, -3.63 to -2.24; $P \le .001$) (Table 2 and Table 3). The superiority of changes favoring the SPLIT program was also found for pain $(\beta_1, -0.88; 95\% \text{ CI}, -1.18 \text{ to } -0.57;$ $P \le .001$), perceived effect of treatment (B, 1.40; 95% CI, 0.97 to 1.82; $P \le .001$), and HRQoL (B, 0.11; 95% CI, 0.08 to 0.14; $P \le .001$). For the proportion of patients who met the MIC and poor disability cutoffs, results also favored the SPLIT program. Sensitivity analysis showed similar results when considering only participants recruited during the implementation plan (Supplemental Table 1 and Supplemental Table 2). Exploratory analysis suggested that whereas for the first cohort, improvements appeared to have been inferior for patients with high risk of poor disability; for the second cohort, benefits of the SPLIT program appeared consistent over the distinct risk subgroups (Supplemental Table 3 and Supplemental Table 4).

Table 2. Primary and Secondar	, Outcomes Over t	he 6-Month Follow-Up
-------------------------------	-------------------	----------------------

	uc	SPLIT
Back-related disability (RMDQ, 0 to 24)		
2 months: UC, n = 110; SPLIT, n = 315		
Mean (SD)	9.14 (6.77)	3.02 (3.81)
Achieved MIC, No. (%) ^a	54 (49.1)	240 (76.2)
Poor disability, No. (%) ^b	64 (58.2)	49 (15.6)
6 months: UC, n = 104; SPLIT, n = 281		
Mean (SD)	8.37 (6.83)	3.06 (4.23)
Achieved MIC, No. (%) ^a	53 (51.0)	210 (74.7)
Poor disability, No. (%) ^b	56 (53.8)	47 (16.7)
Pain intensity (NPRS, 0 to 10)		
2 months: UC, n = 110; SPLIT, n = 315		
Mean (SD)	3.88 (2.90)	1.58 (2.17)
Achieved MIC, No. (%) ^a	55 (50.0)	239 (75.9)
6 months: UC, n = 104; SPLIT, n = 281		
Mean (SD)	3.18 (3.24)	1.83 (2.55)
Achieved MIC, No. (%) ^a	60 (57.7)	195 (69.4)
Perceived effect of treatment (GPES, -5 to +5)		
2 months: UC, n = 110; SPLIT, n = 315		
Median (IQR)	3.0 (4.0)	4.0 (2.0)
Achieved MIC, No. (%) ^a	58 (52.7)	233 (74.0)
6 months: UC, n = 104; SPLIT, n = 281		
Median (IQR)	3.0 (4.0)	4.0 (2.0)
Achieved MIC, No. (%) ^a	56 (53.8)	213 (75.8)
HRQoL (EQ-5D-3L, 0 to 1)		
2 months: UC, n = 110; SPLIT, n = 314		
Mean (SD)	0.61 (0.27)	0.81 (0.21)
6 months: UC, n = 104; SPLIT, n = 281		
Mean (SD)	0.59 (0.25)	0.81 (0.23)

EQ-5D-3L = EuroQoL 5 dimensions 3 levels; GPES = Global Perceived Effect Scale; HRQoL = health-related quality of life; IQR = interquartile range; MIC = minimal important change; NPRS = Numeric Pain Rating Scale; RMDQ = Roland-Morris Disability Questionnaire; SPLIT = stratified primary care for low back pain; UC = usual care.

^a Based on established MIC criteria: \geq 30% decrease from baseline for RMDQ and NPRS and a GPES score \geq 3.

^b Based on a cutoff RMDQ score \geq 7.



Table 3. Effect Estimates for Comparison of Cohorts (SPLIT vs Usual Care) for Primary and Secondary Outcomes Over the 6-Month Follow-Up

	Crude B/OR (95% CI) ^a	P Value	Adjusted B/OR (95% CI) ^a	P Value
	crude Brok (95 % Ci)	r value	Adjusted Brok (99 % Ci)	r value
Back-related disability (RMDQ, 0 to 24)				
Raw score	-5.19 (-6.09 to -4.29)	≤.001	-2.94 (-3.63 to -2.24)	≤.001
Achieved MIC, yes vs no ^b	7.07 (3.31 to 15.08)	≤.001	8.67 (3.98 to 18.89)	≤.001
Poor disability, yes vs no ^c	0.07 (0.003 to 0.13)	≤.001	0.24 (0.15 to 0.38)	≤.001
Pain intensity (NPRS, 0 to 10)				
Raw score	-1.76 (-2.18 to -1.35)	≤.001	-0.88 (-1.18 to -0.57)	≤.001
Achieved MIC, yes vs no ^b	3.55 (1.94 to 6.48)	≤.001	3.50 (1.88 to 6.49)	≤.001
Perceived effect of treatment (GPES, -5 to $+5$)				
Raw score	1.50 (1.08 to 1.91)	≤.001	1.40 (0.97 to 1.82)	≤.001
Achieved MIC, yes vs no ^b	4.66 (2.39 to 9.12)	≤.001	4.40 (2.22 to 8.71)	≤.001
HRQoL (EQ-5D-3L, 0 to 1)				
Raw score	0.19 (0.16 to 0.23)	≤.001	0.11 (0.08 to 0.14)	≤.001

EQ-5D-3L = EuroQoL 5 dimensions 3 levels; GPES = Global Perceived Effect Scale; HRQoL = health-related quality of life; MIC = minimal important change; NPRS = Numeric Pain Rating Scale; OR = odds ratio; RMDQ = Roland-Morris Disability Questionnaire; SPLIT = stratified primary care for low back pain; UC = usual care.

DISCUSSION

In the present before-and-after study, implementation of the SPLIT program for patients with LBP in primary care was associated with greater improvements in back-related disability, pain, perceived effect of treatment, and HRQoL compared with UC over a 6-month follow-up period.

Our results suggest a superior benefit of the SPLIT program vs UC compared to previous studies testing a similar stratified approach in primary care in different countries. 12,14,16-20 Interestingly, our findings occurred even considering the predominant proportion of patients with low risk of poor disability within our sample.

The described benefits challenge the idea that the stratified approach is only successful within the context of UK primary care, where it was initially developed. This was implied after no differences between interventions were found between the United States¹⁸ and Denmark.¹⁹ Specificities of health context and methodologic options might help explain these results. In the United States, despite the comprehensiveness of the implementation plan, 48 only onehalf of the FPs used the SBST, and of those who did, knowledge about each patient's risk did not change the referrals for matched treatments. 18 This might be justified by (1) the predominancy of the training program on general concepts and use of SBST and less on the matched treatments for each risk subgroup, (2) the lack of a clear clinical pathway, especially for medium- and high-risk patients, because distinct clinicians could complete the SBST and treat patients accordingly with numerous treatment options (eg, physical therapy, acupuncture, chiropractic), or (3) the absence of a monitoring program to audit/provide feedback for clinicians responsible for treating patients.⁴⁸ In the present study, both risk stratification and treatment procedures were the PTs' responsibilities alone. In addition, the standardization and structure of the training and mentoring program for these clinicians, along with their lack of experience and confidence in managing musculoskeletal disorders,³¹ might have contributed to the lack of belief regarding alternative interventions and thus potentiated the fidelity to the matched treatments. The average number of physical therapy sessions provided to each risk subgroup, which was aligned with the guidance given to participating PTs, might be indicative of this fidelity to matched treatments.

To the best of our knowledge, this is the first study aiming to implement a stratified approach for LBP in the routine clinical practice of Portuguese primary care. We observed high retention during follow-up. Notwithstanding, several limitations need to be considered. First, this was not a randomized controlled trial, and thus several factors could explain changes in health-related outcomes for the SPLIT cohort. The complexity of the Portuguese health context and the great probability of contamination of the randomization procedure (even with a cluster design given the decreased number of PTs and the same working region), as well as our intention of mirroring routine clinical practice, explain our option for a before-and-after design. Second, the recruitment of participants was based soley on the participating FPs; therefore, selection bias cannot be excluded. This is especially important considering the baseline imbalances observed between cohorts. Despite the adjustments of the effect estimates for these imbalances, results should be interpreted with caution. Measurement (ie, different

^a For continuous outcomes (RMDQ, NPRS, GPES, and EQ-5D-3L raw scores over time), crude/adjusted β values were derived via a linear mixed-effects model for the comparison of UC vs SPLIT. For categorical outcomes (achieved MIC of RMDQ, NPRS, and GPES, along with poor disability), crude/adjusted OR values were derived via a logistic mixed-effects model for the comparison of UC vs SPLIT. Adjusted β/OR and 95% CI values were adjusted for age, duration of low back pain episode, referred leg pain, and baseline STarT Back Screening Tool psychosocial subscale, NPRS, RMDQ, and EQ-5D-3L values.

^b Based on established MIC criteria: ≥30% decrease from baseline for RMDQ and NPRS and a GPES score ≥3.

^c Based on a cutoff RMDQ score ≥7.

assessors between cohorts) and performance bias (ie, more attention given to participants in the SPLIT cohort) also need to be considered. Third, approximately 41% of the referred participants in the SPLIT cohort were excluded, mainly owing to patients' lack of interest in participating or dropouts during the treatment program. Despite anticipation of this barrier,³¹ this might represent proof of selection bias. Fourth, the COVID-19 pandemic period might have had unknown effects on our findings. However, the results of our sensitivity analysis showing a limited effect of this deviation from protocol cannot be ignored. Finally, the change in PTs' behavior was not measured, and we cannot confirm they applied the knowledge that the training and mentoring program entailed.

In the future, investigation of the economic effect of the SPLIT program should be prioritized. The constraints of the COVID-19 pandemic largely hindered access to LBP-related medical records, preventing this analysis.

In conclusion, the implementation of a stratified approach for LBP in Portuguese primary care might promote substantial benefits for patients, supporting the recommendation that further development and implementation of evidence-based managing approaches within local health systems should be prioritized.⁴



Read or post commentaries in response to this article.

Key words: low back pain; stratified care; physical therapy; primary health care; family practice; controlled before-after study

Submitted April 18, 2023; submitted, revised, January 29, 2024; accepted February 2, 2024.

Funding support: This study was funded by the Fundação Ciência e Tecnologia, IP national support via the Comprehensive Health Research Centre (CHRC) (UIDP/04923/2020). Luís Antunes Gomes is supported by the same institution under an individual PhD grant (SFRH/BD/145636/2019).

Previous presentations: Gomes LA, Fernandes R, Caeiro C, et al. CO181 - The SPLIT Stratified Model of Care for Low Back Pain – Results From an Implementation Study in the Portuguese Context Of Primary Healthcare, paper presented at the XXIII Congresso Português de Reumatologia (Portuguese Congress of Rheumatology); October 13-16, 2021; Albufeira, Portugal.

Trial registration: ClinicalTrials.gov: NCT04046874 (August 6, 2019). Retrospectively registered.

Acknowledgments: The team of authors wishes to acknowledge the invaluable support and cooperation of the Regional Health Administration of Lisbon and Tagus Valley (ARS-LVT); clinical boards of the Arrábida Health Center Group (ACeS Arrábida); and the family physicians and physical therapists of the participating health units, their staff, and the patients involved in this study.



Supplemental materials

References

- GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. 10.1016/S0140-6736(20)30925-9. Published correction appears in Lancet. 2020;396(10262):1562. 10.1016/S0140-6736(20)32226-1
- Wu A, March L, Zheng X, et al. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Ann Transl Med. 2020;8(6):299. 10.21037/atm.2020.02.175

- GBD 2021 Low Back Pain Collaborators. Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(6):e316-e329. 10.1016/S2665-9913(23)00098-X
- Traeger AC, Buchbinder R, Elshaug AG, Croft PR, Maher CG. Care for low back pain: can health systems deliver? *Bull World Health Organ*. 2019;97(6):423-433. 10.2471/BLT.18.226050
- Hartvigsen J, Hancock MJ, Kongsted A, et al; Lancet Low Back Pain Series Working Group. What low back pain is and why we need to pay attention. Lancet. 2018;391(10137):2356-2367. 10.1016/S0140-6736(18)30480-X
- Kongsted A, Kent P, Axen I, Downie AS, Dunn KM. What have we learned from ten years of trajectory research in low back pain? BMC Musculoskelet Disord. 2016;17:220. 10.1186/s12891-016-1071-2
- UK National Institute for Health and Care Excellence. Low back pain and sciatica in over 16s: assessment and management. Published Nov 30, 2016. Last updated Dec 11, 2020. Accessed Mar 19, 2024. https://www.nice.org.uk/guidance/ng59/resources/low-back-pain-and-sciatica-in-over-16s-assessment-and-management-pdf-1837521693637
- Van Wambeke P, Desomer A, Ailliet L, et al. Low back pain and radicular pain: evaluation and management. Belgian Health Care Knowledge Centre. Published 2017. Accessed Mar 25, 2021. https://www.kce.fgov.be/en/publications/all-reports/low-back-pain-and-radicular-pain-evaluation-and-management
- Corp N, Mansell G, Stynes S, et al. Evidence-based treatment recommendations for neck and low back pain across Europe: a systematic review of guidelines. Eur J Pain. 2021;25(2):275-295. 10.1002/EJP.1679
- Foster NE, Anema JR, Cherkin D, et al; Lancet Low Back Pain Series Working Group. Prevention and treatment of low back pain: evidence, challenges, and promising directions. *Lancet.* 2018;391(10137):2368-2383. 10.1016/ S0140-6736(18)30489-6
- Hill JC, Dunn KM, Lewis M, et al. A primary care back pain screening tool: identifying patient subgroups for initial treatment. Arthritis Rheum. 2008;59(5): 632-641. 10.1002/ART.23563
- 12. Hill JC, Whitehurst DGT, Lewis M, et al. Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial. *Lancet*. 2011;378(9802):1560-1571. 10.1016/s0140-6736(11)60937-9
- Whitehurst DGT, Bryan S, Lewis M, Hill J, Hay EM. Exploring the cost-utility of stratified primary care management for low back pain compared with current best practice within risk-defined subgroups. *Ann Rheum Dis*. 2012;71(11): 1796-1802. 10.1136/ANNRHEUMDIS-2011-200731
- Foster NE, Mullis R, Hill JC, et al; IMPaCT Back Study team. Effect of stratified care for low back pain in family practice (IMPaCT Back): a prospective population-based sequential comparison. *Ann Fam Med*. 2014;12(2):102-111. 10.1370/afm.1625
- 15. Whitehurst DGT, Bryan S, Lewis M, Hay EM, Mullis R, Foster NE. Implementing stratified primary care management for low back pain: cost-utility analysis alongside a prospective, population-based, sequential comparison study. *Spine (Phila Pa 1976)*. 2015;40(6):405-414. 10.1097/BRS.00000000000000770
- Murphy SE, Blake C, Power CK, Fullen BM. The effectiveness of a stratified group intervention using the STarTBack screening tool in patients with LBP a non randomised controlled trial. BMC Musculoskelet Disord. 2013;14:342. 10.1186/1471-2474-14-342
- Beneciuk JM, George SZ. Pragmatic implementation of a stratified primary care model for low back pain management in outpatient physical therapy settings: two-phase, sequential preliminary study. *Phys Ther.* 2015;95(8):1120-1134. 10.2522/ptj.20140418
- 18. Cherkin D, Balderson B, Wellman R, et al. Effect of low back pain risk-stratification strategy on patient outcomes and care processes: the MATCH randomized trial in primary care. *J Gen Intern Med.* 2018;33(8):1324-1336. 10.1007/s11606-018-4468-9
- Morsø L, Olsen Rose K, Schiøttz-Christensen B, Sowden G, Søndergaard J, Christiansen DH. Effectiveness of stratified treatment for back pain in Danish primary care: a randomized controlled trial. Eur J Pain. 2021;25(9):2020-2038. 10.1002/ejp.1818
- Rhon DI, Greenlee TA, Poehlein E, et al. Effect of risk-stratified care on disability among adults with low back pain treated in the military health system: a randomized clinical trial. JAMA Netw Open. 2023;6(7):e2321929. 10.1001/ JAMANETWORKOPEN.2023.21929

- Cruz EB, Canhão H, Fernandes R, et al. Prognostic indicators for poor outcomes in low back pain patients consulted in primary care. PLoS One. 2020; 15(3):e0229265. 10.1371/journal.pone.0229265
- Gomes LA, Cruz EB, Henriques AR, Branco JC, Canhão H, Rodrigues AM. Patients' self-reported medical care for low back pain: a nationwide population-based study. *BMJ Open.* 2022;12(9):e060966. <u>10.1136/BMJOPEN-2022-060966</u>
- US National Library of Medicine. Stratified Primary Care for Low Back Pain (SPLIT). ClinicalTrials.gov. Last updated Aug 4, 2020. https://clinicaltrials.gov/ct2/show/study/NCT04046874
- 24. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. *Lancet*. 2017;389(10070):736-747. 10.1016/S0140-6736(16)30970-9
- Koes BW, van Tulder MW, Thomas S. Diagnosis and treatment of low back pain. BMJ. 2006;332(7555):1430-1434. 10.1136/bmj.332.7555.1430
- Hay EM, Dunn KM, Hill JC, et al. A randomised clinical trial of subgrouping and targeted treatment for low back pain compared with best current care. The STarT Back Trial Study Protocol. BMC Musculoskelet Disord. 2008;9:58. 10.1186/1471-2474-9-58
- Alrwaily M, Timko M, Schneider M, et al. Treatment-based classification system for low back pain: revision and update. *Phys Ther*. 2016;96(7):1057-1066. 10.2522/ptj.20150345
- Alrwaily M, Timko M, Schneider M, et al. Treatment-based classification system for patients with low back pain: the movement control approach. *Phys Ther.* 2017;97(12):1147-1157. 10.1093/ptj/pzx087
- White CA. Cognitive behavioral principles in managing chronic disease. West J Med. 2001;175(5):338-342. 10.1136/ewjm.175.5.338
- Raimundo A, Parraça J, Batalha N, et al. Portuguese translation, cross-cultural adaptation and reliability of the questionnaire "Start Back Screening Tool" (SBST). Acta Reumatol Port. 2017;42(1):38-46.
- 31. Caeiro C, Canhão H, Paiva S, et al. Interdisciplinary stratified care for low back pain: a qualitative study on the acceptability, potential facilitators and barriers to implementation. *PLoS One*. 2019;14(11):e0225336. 10.1371/journal.pone.0225336
- Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee
 of the American College of Physicians; Denberg TD, Barry MJ, Boyd C, et al.
 Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Inter Med.
 2017;166(7):514-530. 10.7326/M16-2367
- Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Eur Spine J. 2018;27(1):60-75. 10.1007/s00586-017-5099-2
- 34. George SZ, Fritz JM, Silfies SP, et al. Interventions for the Management of Acute and Chronic Low Back Pain: Revision 2021. *J Orthop Sports Phys Ther.* 2021;51(11):CPG1-CPG60. 10.2519/jospt.2021.0304

- 35. Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine (Phila Pa 1976). 1983;8(2):141-144. 10.1097/00007632-198303000-00004
- Grotle M, Brox JI, Vøllestad NK. Cross-cultural adaptation of the Norwegian versions of the Roland-Morris Disability Questionnaire and the Oswestry Disability Index. J Rehabil Med. 2003;35(5):241-247. 10.1080/16501970306094
- 37. Monteiro J, Faísca L, Nunes O, Hipólito J. [Roland Morris disability questionnaire adaptation and validation for the Portuguese speaking patients with back pain]. *Acta Med Port.* 2010;23(5):761-766. Article in Portuguese. Abstract in English.
- 38. Jensen MP, Turner JA, Romano JM. What is the maximum number of levels needed in pain intensity measurement? *Pain*. 1994;58(3):387-392. 10.1016/0304-3959(94)90133-3
- Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149-158. 10.1016/S0304-3959(01)00349-9
- Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric pain rating scale in patients with low back pain. Spine (Phila Pa 1976). 2005;30(11):1331-1334. 10.1097/01.brs.0000164099.92112.29
- 41. Ferreira PL, Ferreira LN, Pereira LN. [Contribution for the validation of the Portuguese version of EQ-5D]. *Acta Med Port.* 2013;26(6):664-75. Article in Portuguese. Abstract in English.
- 42. EuroQol Research Foundation. EQ-5D-5L User Guide: Basic Information on How to Use the EQ-5D-5L Instrument. Version 3.0. Updated Sep 2019. https://euroqol.org/wp-content/uploads/2023/11/EQ-5D-5LUserguide-23-07.pdf
- Ferreira LN, Ferreira PL, Pereira LN, Oppe M. The valuation of the EQ-5D in Portugal. Qual Life Res. 2014;23(2):413-423. 10.1007/s11136-013-0448-z
- 44. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. *J Man Manip Ther.* 2009;17(3):163-170. 10.1179/JMT.2009.17.3.163
- 45. Costa LOP, Maher CG, Latimer J, et al. Clinimetric testing of three self-report outcome measures for low back pain patients in Brazil: which one is the best? Spine (Phila Pa 1976). 2008;33(22):2459-2463. 10.1097/BRS.0b013e3181849 dbe
- 46. Freitas P, Pires D, Nunes C, Cruz EB. Cross-cultural adaptation and psychometric properties of the European Portuguese version of the Global Perceived Effect Scale in patients with chronic low back pain. *Disabil Rehabil*. 2021;43(7): 1008-1014. 10.1080/09638288.2019.1648568
- 47. Ostelo RW, Deyo RA, Stratford P, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine (Phila Pa 1976). 2008;33(1):90-94. 10.1097/BRS.0b013e31815e3a10
- 48. Hsu C, Evers S, Balderson BH, et al. Adaptation and implementation of the STarT Back risk stratification strategy in a US health care organization: a process evaluation. *Pain Med.* 2019;20(6):1105-1119. 10.1093/pm/pny170